Free Trial
NASDAQ:AIKI

AIkido Pharma (AIKI) Stock Price, News & Analysis

AIkido Pharma logo
$2.00 -0.01 (-0.25%)
As of 01/28/2025

About AIkido Pharma Stock (NASDAQ:AIKI)

Key Stats

Today's Range
$1.73
$2.05
50-Day Range
$0.90
$3.56
52-Week Range
$3.31
$11.48
Volume
274,907 shs
Average Volume
79,326 shs
Market Capitalization
$10.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Stock News Headlines

SNOA Sonoma Pharmaceuticals, Inc.
Royalty Pharma PLC
Grab This Altcoin Before Trump's Crypto Announcement
The #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of a lifetime!
Dominari Holdings Inc. Releases Shareholder Update
Kyle Wool Appears on Fox Business
Dominari Holdings Appoints George Way As CFO
See More Headlines

AIKI Stock Analysis - Frequently Asked Questions

AIkido Pharma's stock was trading at $0.9844 at the start of the year. Since then, AIKI stock has increased by 102.7% and is now trading at $1.9950.
View the best growth stocks for 2025 here
.

Shares of AIkido Pharma reverse split on Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

The following companies are subsidiaries of AIkido Pharma: Hoth Therapeutics.

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AIkido Pharma investors own include Atossa Therapeutics (ATOS), iBio (IBIO), Bionano Genomics (BNGO), Ocugen (OCGN), Meta Platforms (META), Cineverse (CNVS) and

Company Calendar

Today
1/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:AIKI
Employees
4
Year Founded
1967

Profitability

Net Income
$-7,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$19.27 per share

Miscellaneous

Free Float
5,013,000
Market Cap
$10.94 million
Optionable
Not Optionable
Beta
0.93

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:AIKI) was last updated on 1/30/2025 by MarketBeat.com Staff
From Our Partners